AstraZeneca sees stock market value slump by more than £20bn after drug setback

The Argus — Jul 09, 10:39 AM

The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.

Read full article at The Argus →

AstraZeneca Shares Plunge on Drug Trial Failure

AstraZeneca stock plunges after late-stage heart drug trial misses its target Quartz — Jul 09, 11:20 AM
AstraZeneca sees stock market value slump by more than £20bn after drug setback Yorkshire Post — Jul 09, 10:47 AM